Skip to main content
Meta navigation
Contact
Donate
Jobs
Main navigation
Home
For patients
For researchers
About us
Lung cancer
6 currently open clinical trials
Osimertinib and bevacizumab versus osimertinib alone for patients with non-small cell lung cancer
ETOP BOOSTER
Anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with lung cancer
EORTC PEARLS
Dosage of a new targeted drug for the treatment of lung cancer
SAKK 19/16
Durvalumab in patients with advanced lung cancer and poor general state of health
SAKK 19/17
Single arm phase II trial evaluating the activity of Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC
ETOP ALERT
Phase III study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 Involvement
LUNGART EORTC
All cancer types
Mobile main navigation
Home
For patients
For patients
Participate in a trial
Genetic Counceling
FAQ
Glossary
Downloads
For researchers
For researchers
Research groups
Young Oncology Academy
Grants and fellowships
Electronic Data Capture (EDC)
About us
About us
Mission statement
Organization
Board and Executive Board
Patient Advisory Board
Support and collaborations
Media and publications
Mobile meta navigation
Contact
Donate
Jobs
Vacancies
Work for us
Our values
Work–life balance
Wages and benefits
Staff development
Mobile footer navigation
Imprint
EN
DE
FR
Mobile quicklinks
Trials
Events
News
Members
Quicklinks
Trials
Events
News
Members